

Teresa Alonso-Gordoa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6686222/publications.pdf>

Version: 2024-02-01

46
papers

697
citations

686830

13
h-index

610482

24
g-index

46
all docs

46
docs citations

46
times ranked

1105
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting HIF-2 $\hat{\pm}$ in clear cell renal cell carcinoma: A promising therapeutic strategy. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 111, 117-123.	2.0	90
2	Open-Label, Single-Arm Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Clear Cell Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 1020-1028.	0.8	83
3	Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 2571-2580.	0.8	49
4	Tyrosine Kinase Receptors in Oncology. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8529.	1.8	46
5	BRAF Mutated Colorectal Cancer: New Treatment Approaches. <i>Cancers</i> , 2020, 12, 1571.	1.7	44
6	Targeting Tyrosine kinases in Renal Cell Carcinoma: "New Bullets against Old Guys" <i>International Journal of Molecular Sciences</i> , 2019, 20, 1901.	1.8	41
7	Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: a Spanish multicenter experience. <i>Future Oncology</i> , 2017, 13, 615-624.	1.1	32
8	Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma. <i>Cancers</i> , 2021, 13, 5981.	1.7	31
9	The PALBONET Trial: A Phase II Study of Palbociclib in Metastatic Grade 1 and 2 Pancreatic Neuroendocrine Tumors (GETNE-1407). <i>Oncologist</i> , 2020, 25, 745-e1265.	1.9	25
10	Exome array analysis identifies ETFB as a novel susceptibility gene for anthracycline-induced cardiotoxicity in cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 167, 249-256.	1.1	23
11	Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. <i>Oncologist</i> , 2016, 21, 701-707.	1.9	22
12	New oncologic emergencies: What is there to know about immunotherapy and its potential side effects?. <i>European Journal of Internal Medicine</i> , 2019, 66, 1-8.	1.0	19
13	Immunotherapy in Adrenocortical Carcinoma: Predictors of Response, Efficacy, Safety, and Mechanisms of Resistance. <i>Biomedicines</i> , 2021, 9, 304.	1.4	16
14	Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. <i>International Journal of Molecular Sciences</i> , 2019, 20, 4949.	1.8	15
15	Emerging use of everolimus in the treatment of neuroendocrine tumors. <i>Cancer Management and Research</i> , 2017, Volume 9, 215-224.	0.9	14
16	First-line pembrolizumab (pembro) monotherapy in advanced clear cell renal cell carcinoma (ccRCC): Updated results for KEYNOTE-427 cohort A.. <i>Journal of Clinical Oncology</i> , 2019, 37, 4570-4570.	0.8	14
17	Translating new data to the daily practice in second line treatment of renal cell carcinoma: The role of tumor growth rate. <i>World Journal of Clinical Oncology</i> , 2017, 8, 100.	0.9	14
18	Resistance to RET targeted therapy in Thyroid Cancer: Molecular basis and overcoming strategies. <i>Cancer Treatment Reviews</i> , 2022, 105, 102372.	3.4	13

#	ARTICLE	IF	CITATIONS
19	Sunitinib and Evofosfamide (<sc>TH</sc>-302) in Systemic Treatment-Na ⁺ ve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The <sc>GETNE</sc>-1408 Trial. <i>Oncologist</i> , 2021, 26, 941-949.	1.9	12
20	Treatment outcomes of advanced digestive well-differentiated grade 3 NETs. <i>Endocrine-Related Cancer</i> , 2021, 28, 549-561.	1.6	10
21	Primary Sarcomatoid Tumor of the Bladder: A Different Entity but the Same Approach?. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 493-498.	0.9	7
22	Current and Future Role of Tyrosine Kinases Inhibition in Thyroid Cancer: From Biology to Therapy. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4951.	1.8	7
23	Novel Tyrosine Kinase Targets in Urothelial Carcinoma. <i>International Journal of Molecular Sciences</i> , 2021, 22, 747.	1.8	6
24	The effect of medical and urologic disorders on the survival of patients with metastatic castration resistant prostate cancer treated with abiraterone or enzalutamide. <i>Therapeutic Advances in Urology</i> , 2021, 13, 175628722110433.	0.9	6
25	External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study. <i>Neuroendocrinology</i> , 2022, 112, 88-100.	1.2	6
26	Primary Neuroendocrine Tumor of the Parotid Gland: A Case Report and a Comprehensive Review of a Rare Entity. <i>Case Reports in Otolaryngology</i> , 2016, 2016, 1-5.	0.1	5
27	May Ibrutinib Have Activity in Respiratory Complications by SARS-CoV-2? Clinical Experience in a Patient with Chronic Lymphocytic Leukemia. <i>Healthcare (Switzerland)</i> , 2021, 9, 78.	1.0	5
28	The SUNEVO (GETNE-1408) trial to evaluate the activity and safety of the combination of sunitinib with evofosfamide (TH-302) in patients with G1/G2 metastatic pancreatic neuroendocrine tumours (pNETs) na ⁺ ve for systemic treatment: A phase II study of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumors (GETNE).. <i>Journal of Clinical Oncology</i> , 2019, 37, 4105-4105.	0.8	5
29	DUTRENEO Trial: A phase II randomized trial of DUrvalumab and TREmelimumab as NEOadjuvant approach in muscle-invasive urothelial bladder cancer (MIBC) patients prospectively selected by immune signature scores.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4588-TPS4588.	0.8	5
30	A case series of advanced renal cell carcinoma patients treated with neoadjuvant cabozantinib prior to cytoreductive nephrectomy within the phase 2 CABOPRE trial. <i>Oncotarget</i> , 2020, 11, 4457-4462.	0.8	5
31	An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). <i>Rare Cancers and Therapy</i> , 2015, 3, 13-33.	0.2	4
32	Inhibition of Serotonin Synthesis May Have Antitumor Activity? Long ⁺ Term Efficacy in a Patient with Gastrointestinal Neuroendocrine Tumor. <i>Oncologist</i> , 2019, 24, e597-e599.	1.9	4
33	Special situations in pheochromocytomas and paragangliomas: pregnancy, metastatic disease, and cyanotic congenital heart diseases. <i>Clinical and Experimental Medicine</i> , 2022, 22, 359-370.	1.9	4
34	Time-of-day infusion of immunotherapy in metastatic urothelial cancer (mUC): Should it be considered to improve survival outcomes?. <i>Journal of Clinical Oncology</i> , 2022, 40, e16541-e16541.	0.8	4
35	Advanced small-bowel well-differentiated neuroendocrine tumours: An international survey of practice on 3 rd -line treatment. <i>World Journal of Gastroenterology</i> , 2021, 27, 976-989.	1.4	3
36	Hyperprogression to a dual immune blockade followed by subsequent response with cabozantinib in metastatic poor-risk clear cell renal cell carcinoma with NOTCH mutation. <i>Oncotarget</i> , 2020, 11, 2137-2140.	0.8	2

#	ARTICLE	IF	CITATIONS
37	Genomic Landscape of Vinflunine Response in Metastatic Urothelial Cancer. <i>Cancers</i> , 2022, 14, 378.	1.7	2
38	High-Dose Somatostatin Analogs for the Treatment of Neuroendocrine Neoplasms: where are we Now?. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1001-1013.	1.3	2
39	Tumor-associated macrophages: "Good cop" or "bad cop"? <i>Cancer</i> , 2019, 125, 1941-1942.	2.0	1
40	Does timing of Immune checkpoint inhibitors (ICIs) administration in first line Metastatic Renal Cell Carcinoma (mRCC) have impact in survival outcomes?. <i>Journal of Clinical Oncology</i> , 2022, 40, e16512-e16512.	0.8	1
41	Phalangeal metastasis in colon adenocarcinoma. <i>Medicina Clínica</i> , 2019, 152, e23.	0.3	0
42	In Reply. <i>Oncologist</i> , 2020, 25, e1259-e1259.	1.9	0
43	Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2021, 39, 5024-5024.	0.8	0
44	Association of immune gene expression profiling with vinflunine clinical benefit in metastatic urothelial cancer (mUC).. <i>Journal of Clinical Oncology</i> , 2019, 37, e16034-e16034.	0.8	0
45	Vigilancia clínica de los pacientes que reciben inmunoterapia. <i>Medicina Clínica</i> , 2020, 154, 493-495.	0.3	0
46	Diagnosis in Neuroendocrine Neoplasms: From Molecular Biology to Molecular Imaging. <i>Cancers</i> , 2022, 14, 2514.	1.7	0